KCPG
ACAD icon

Kavar Capital Partners Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Kavar Capital Partners Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6
Closed – – 102
2015
Q4 		$0 Hold
6
– – ﹤0.01% 474
2015
Q3 		$0 Sell
6
-2
-25% -$83 ﹤0.01% 478
2015
Q2 		$0 Buy
+8
New +$310 ﹤0.01% 513
2014
Q2 		– Sell
-10
Closed – – 133
2014
Q1 		$0 Hold
10
– – ﹤0.01% 526
2013
Q4 		$0 Buy
+10
New +$236 ﹤0.01% 498

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Kavar Capital Partners Group's ACAD Position: Q1 2016 in Review

Kavar Capital Partners Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2016, closing a stake of 6 shares.

Kavar Capital Partners Group first reported a position in ACAD in Q4 2013 and held it in 5 quarters. The position peaked at $0 in Q4 2015. 213 funds tracked by Wall St. Rank hold ACAD as of Q1 2016.

  • Kavar Capital Partners Group reported no remaining Acadia Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Kavar Capital Partners Group sold 6 Acadia Pharmaceuticals shares in Q1 2016.
  • Kavar Capital Partners Group first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Kavar Capital Partners Group's Acadia Pharmaceuticals position peaked at $0 in Q4 2015.
  • 213 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2016.

Based on Kavar Capital Partners Group's 13F filing for Q1 2016, filed 13 May 2019.